Business Details
13 Years
experience
Your Trusted Partner for Cost-Effective Pharmaceutical Solutions
Stirling Anglian Pharmaceuticals was founded in 2013 with a clear mission to deliver innovative, value-added medicines to the UK healthcare system. Our focus lies in addressing critical challenges faced by the NHS, including cost efficiency and medication waste reduction. By collaborating closely with NHS stakeholders, we identify real-world problems and develop tailored solutions that enhance patient care while optimising resource allocation. Our portfolio of high-quality, patient-centric medicines is designed to improve health outcomes and streamline healthcare delivery. With a commitment to excellence, we specialise in respiratory, gastrointestinal, musculoskeletal, and nutritional therapies, ensuring compliance and convenience for patients.As part of the Kelso Pharma Group since 2022, we continue to expand our impact through strategic partnerships and a dedication to sustainable practices. Our team combines deep industry expertise with a passion for innovation, driving measurable improvements in healthcare accessibility and affordability. Every product we develop reflects our core values of integrity, responsibility, and a relentless focus on patient needs.
Services
Respiratory Medicines
Gastrointestinal Treatments
Musculoskeletal Therapies
Nutritional Supplements
Dermatology Products
Details
- Year established: 2013
Highlights and features
- We develop medicines specifically designed to reduce NHS waste and costs.
- Our products improve patient compliance through user-friendly formulations.
- We collaborate directly with NHS stakeholders to address real-world challenges.
- Our portfolio includes proven treatments for respiratory, GI, and musculoskeletal conditions.
- We are part of the Kelso Pharma Group, enhancing our research and development capabilities.
Services
Respiratory Medicines
Our respiratory medicines, including Acepiro (acetylcysteine 600mg effervescent tablets), are designed to treat chronic respiratory conditions by reducing mucus viscosity. These formulations improve patient compliance through easy-to-use effervescent tablets that dissolve in water. Our solutions support the NHS in managing respiratory diseases more efficiently while enhancing patient quality of life.
Gastrointestinal Treatments
Our gastrointestinal treatments, such as CosmoCol and CosmoCol Half, address constipation and faecal impaction with macrogol-based laxatives. These products feature palatable flavours and precise dosing to ensure patient adherence. By optimising treatment protocols, we help reduce hospital admissions and improve digestive health outcomes across adult and paediatric populations.
Musculoskeletal Therapies
Stirlescent (naproxen 250mg effervescent tablets) provides targeted relief for musculoskeletal and joint conditions. The effervescent formulation ensures rapid absorption and ease of use, particularly beneficial for patients with swallowing difficulties. Our therapies aim to enhance mobility and reduce pain, supporting long-term musculoskeletal health.
Nutritional Supplements
theiCal-D3 (calcium/vitamin D3 chewable tablets) offers a convenient solution for preventing and treating deficiencies in elderly patients. The chewable format improves compliance, while its Halal-certified, vegetarian-friendly formulation caters to diverse dietary needs. Clinical evidence supports its efficacy in managing osteoporosis and vitamin D deficiency.
Dermatology Products
Our dermatology portfolio includes prescription medicines for actinic keratoses and plaque psoriasis. These treatments target unmet clinical needs with innovative formulations that improve skin health outcomes. Backed by rigorous regulatory approvals, our products provide dermatologists with reliable options for managing complex skin conditions effectively.
Questions
What is Stirling Anglian Pharmaceuticals' core mission?
Our mission is to deliver innovative, cost-effective medicines that reduce NHS waste and improve patient outcomes through value-based solutions.
How do your products help the NHS?
Our medicines address compliance issues, reduce medication waste, and lower healthcare costs while maintaining high therapeutic standards.
Are your medicines available outside the UK?
We are expanding into the CIS market and pursuing regulatory approvals in the Middle East and North Africa.
How can I report side effects of your products?
Report adverse events via the MHRA Yellow Card Scheme or contact our pharmacovigilance team directly using the details provided.
What makes your formulations unique?
Our effervescent and chewable tablets improve patient compliance, with user-friendly designs that simplify administration and enhance treatment adherence.
How are you addressing sustainability?
We prioritise sustainable practices in manufacturing and supply chain management to reduce environmental impact while maintaining product quality.
